| PRKCA — Protein Kinase C Alpha | |
|---|---|
| Gene Symbol | PRKCA |
| Full Name | Protein Kinase C Alpha |
| Chromosome | 17q24.2 |
| NCBI Gene ID | 5578 |
| UniProt ID | P17252 |
| Protein Family | PKC family, AGC kinase group |
| Molecular Weight | 76.8 kDa |
| Disease Relevance | [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), Schizophrenia, Cancer |
Protein Kinase C Alpha (PKCα), encoded by the PRKCA gene, is a member of the protein kinase C family of serine/threonine kinases 1. PKCα is a conventional (cPKC) isoform that requires diacylglycerol (DAG), calcium, and phosphatidylserine for full activation 2. This enzyme plays crucial roles in various cellular signaling pathways that regulate proliferation, differentiation, apoptosis, and synaptic plasticity 3.
PKCα is one of the most widely expressed PKC isoforms, found in virtually all cell types including neurons, glia, and immune cells 4. In the central nervous system, PKCα is particularly important for regulating synaptic transmission, neuronal excitability, and processes related to learning and memory 5. Dysregulation of PKCα has been implicated in multiple neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and schizophrenia 6.
PKCα contains multiple functional domains:
Regulatory Domain:
Catalytic Domain:
PKCα activation follows a sequential process:
Step 1: Membrane Recruitment:
Step 2: DAG Binding:
Step 3: Catalytic Activation:
PKCα is regulated by multiple phosphorylations:
Phosphorylation at Three Sites:
Other Modifications:
PKCα phosphorylates numerous substrate proteins:
Substrate Specificity:
Downstream Effectors:
PKCα participates in multiple signaling cascades:
G-protein Coupled Receptor (GPCR) Signaling:
Growth Factor Signaling:
Integrin Signaling:
PKCα critically regulates synaptic plasticity:
Long-term Potentiation (LTP):
Long-term Depression (LTD):
Learning and Memory:
PKCα modulates various ion channels:
NMDA Receptors:
AMPA Receptors:
Voltage-gated Calcium Channels:
PKCα has complex effects on neuronal viability:
Pro-survival Functions:
Pro-apoptotic Functions:
PKCα is implicated in AD pathogenesis:
Amyloid Processing:
Tau Phosphorylation:
Synaptic Dysfunction:
Therapeutic Implications:
PKCα contributes to PD pathophysiology:
Dopaminergic Neuron Survival:
Alpha-synuclein Aggregation:
Mitochondrial Dysfunction:
PKCα dysregulation in schizophrenia:
Redistribution:
Therapeutic Targets:
Pharmacological approaches targeting PKCα:
Activators:
Inhibitors:
Cancer Therapy:
Neurodegeneration:
In Vitro Kinase Assays:
In Vivo Phosphorylation:
Cell Fractionation:
Live Cell Imaging:
Knockout Mice:
Conditional Knockouts:
Transgenic Models:
PKCα is highly conserved:
Human and Mouse:
Other Mammals:
Other PKC Isoforms:
Functional Differences:
PRKCA encodes Protein Kinase C Alpha (PKCα), a conventional (calcium- and DAG-dependent) serine/threonine kinase that plays critical roles in neuronal signaling, synaptic plasticity, and cell survival. PKCα is activated by GPCRs and growth factor receptors, phosphorylates numerous substrate proteins, and participates in diverse cellular processes. In the central nervous system, PKCα regulates NMDA and AMPA receptor function, controls synaptic plasticity, and contributes to learning and memory. Dysregulation of PKCα is implicated in Alzheimer's disease, Parkinson's disease, and schizophrenia. Targeting PKCα with pharmacological modulators offers therapeutic potential for these disorders, though achieving isoform and context-specific effects remains a challenge.
PKCα as a biomarker:
Diagnostic Applications:
Therapeutic Monitoring:
Challenges in PKC drug development:
Selectivity Issues:
Toxicity Considerations:
Delivery Challenges:
Functional Variants:
Germline Knockout:
Conditional Knockouts:
Transgenic Overexpression:
Protein Handling:
Assay Conditions:
Structure-Activity Relationships:
PRKCA encodes Protein Kinase C Alpha, a critical serine/threonine kinase involved in neuronal signaling, synaptic plasticity, and cell survival. Its dysregulation contributes to multiple neurodegenerative diseases, making it an important therapeutic target. Despite challenges in achieving isoform-selective targeting, ongoing research continues to advance our understanding of PKCα function and develop better therapeutic modulators.
[@newton1995]: Newton, Protein kinase C (1995)
[@hannun1996]: Hannun, The PKC superfamily (1996)
[@alonso2002]: Alonso et al., PKC in cell signaling (2002)
[@mackay2003]: Mackay & Twelves, PKC in cancer (2003)
[@saitoh2001]: Saitoh et al., PKC in synaptic plasticity (2001)
[@steinberg2008]: Steinberg, PKC isoforms in disease (2008)
[@sharkey1998]: Sharkey & Blumberg, PKC structure (1998)
[@kazanietz2002]: Kazanietz, C1 domain (2002)
[@newton2001]: Newton, PKC activation (2001)
[@giorgione1999]: Giorgione & Hannun, DAG binding (1999)
[@keranen1995]: Keranen et al., PKC autophosphorylation (1995)
[@dutil1998]: Dutil et al., PKC phosphorylation (1998)
[@gould2009]: Gould et al., PKC degradation (2009)
[@nishikawa1997]: Nishikawa et al., PKC substrates (1997)
[@saitoh2000]: Saitoh et al., PKC effectors (2000)
[@rhee1999]: Rhee & Choi, PLC signaling (1999)
[@leondaritis2009]: Leondaritis et al., PKC and growth factors (2009)
[@werlen2003]: Werlen et al., PKC in migration (2003)
[@malenka1996]: Malenka et al., PKC and LTP (1996)
[@man2006]: Man et al., PKC and LTD (2006)
[@abeliovich1993]: Abeliovich et al., PKC and memory (1993)
[@leonard2002]: Leonard et al., PKC and NMDA receptors (2002)
[@boehm2006]: Boehm et al., PKC and AMPA receptors (2006)
[@weiss2002]: Weiss et al., PKC and calcium channels (2002)
[@zhang2007]: Zhang et al., PKC and survival (2007)
[@gutcher2003]: Gutcher et al., PKC apoptosis (2003)
[@chao1997]: Chao et al., PKC and APP (1997)
[@liu2009]: Liu et al., PKC and tau (2009)
[@moss2005]: Moss et al., PKC in AD (2005)
[@etcheberria2006]: Etcheberria et al., PKC activators in AD (2006)
[@zhang2005]: Zhang et al., PKC in PD (2005)
[@qin2006]: Qin et al., PKC and alpha-synuclein (2006)
[@brenman2005]: Brenman et al., PKC mitochondria (2005)
[@harrison2008]: Harrison & Chen, PKC in schizophrenia (2008)
[@shearman1999]: Shearman et al., PKC psychotomimetic (1999)
[@kazunori2000]: Kazunori & Hannun, PKC activators (2000)
[@khalil2005]: Khalil et al., PKC inhibitors (2005)
[@mackay2007]: Mackay, PKC in cancer therapy (2007)
[@sun2005]: Sun & Alkon, PKC neuroprotection (2005)
[@kikkawa1983]: Kikkawa et al., PKC assay (1983)
[@kelley2009]: Kelley et al., Phosphoproteomics (2009)
[@kraft1983]: Kraft & Anderson, PKC translocation (1983)
[@violin2006]: Violin et al., FRET sensors (2006)
[@abeliovich1995]: Abeliovich et al., PKC knockout (1995)
[@tanaka2000]: Tanaka & Soderling, Conditional knockout (2000)
[@meller2002]: Meller et al., Transgenic PKC (2002)
[@stabel1991]: Stabel & Parker, PKC isoforms (1991)
[@nishizuka1988]: Nishizuka, PKC family (1988)
[@mellor1998]: Mellor & Parker, PKC classification (1998)
[@humphries2006]: Humphries et al., PKC redundancy (2006)
[@griner2009]: Griner & Kazanietz, New PKC research (2009)